Immunofoco

Executive Summary

Immunofoco is a Chinese biopharmaceutical company advancing novel antibody-based therapeutics and vaccines for oncology and infectious diseases. Founded in 2019, the company has built a proprietary antibody discovery engine and internal GMP manufacturing capabilities, enabling end-to-end development from discovery to clinical supply. Its pipeline includes monoclonal antibodies, antibody-drug conjugates (ADCs), and viral vaccine candidates, with several programs having reached Phase 3 clinical trials. The company went public recently, reflecting investor confidence in its platform and late-stage assets. Immunofoco's integrated approach and focus on high-need areas position it as a potential leader in China's biotech ecosystem, though commercial execution and regulatory dynamics remain key risks.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 data readout for lead oncology antibody60% success
• Q1 2027BLA submission for infectious disease vaccine candidate70% success
• H2 2026Strategic partnership for ADC platform50% success